Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.jCr9XYTz.js ...
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
Viking Therapeutics: Investors Meeting Reality Of The Obesity Market
Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.
Allurion stock soars 70% on weight-loss therapy update
Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...
Medscape7h
Obesity Medications: Who Needs Priority Access
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
24/7 Wall St. on MSN6h
I Was Convinced Biotech Stocks Were Too Risky—This Innovation's Changing the Game
The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough to gauge which innovative biotech firms will have something genuinely ground ...